The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity

Antigen heterogeneity that results in tumor antigenic escape is one of the major obstacles to successful chimeric antigen receptor (CAR) T cell therapies in solid tumors including glioblastoma multiforme (GBM). To address this issue and improve the efficacy of CAR T cell therapy for GBM, we develope...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Edward Z. Song, Xin Wang, Benjamin I. Philipson, Qian Zhang, Radhika Thokala, Logan Zhang, Charles-Antoine Assenmacher, Zev A. Binder, Guo-li Ming, Donald M. O’Rourke, Hongjun Song, Michael C. Milone
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2022-12-01
coleção:	Molecular Therapy: Oncolytics
Assuntos:	IAP antagonist birinapant CAR T cell glioblastoma antigen heterogeneity
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2372770522001395
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!